HIV Drug Market to Reach $26,458 Million, Globally by 2022
Read more at: https://www.alliedmarketresearch.com/press-release/hiv-drugs-market.html
HIV Drug Market report, published by Allied Market Research, forecasts that the global market is expected to garner $26,458 million by 2022, registering a CAGR of 3.7% during the period 2016 - 2022. The multi-class combination drug segment held over one-third share of the total market in 2015.
Multi-class combination drugs segment had accounted for more than one-third revenue of the overall HIV drug market in 2015, owing to increase in adoption of combination drugs from this medication class due to their better results in the control of HIV & related coinfections and their ease in consumption & adherence. Increase in the number of HIV infected patients across the globe increases the need for effective treatment for HIV related diseases. Use of Multi-class combination products is an efficient way of treating HIV. Atripla and Prezista are among the blockbuster combination drugs used in the HIV treatment.
Request for free sample of report at: https://www.alliedmarketresearch.com/request-free-sample/1867
